primary immune thrombocytopenia
Conditions
Interventions
Case series:PKA agonist (aminophylline) treats chronic or refractory primary immune thrombocytopenia
Sponsors
Department of Hematology, The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
11 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged between 11 to 65 years male and female; 2. The clinical diagnosis is refractory or chronic ITP patients which need treatment (platelet count < 30 x 10^9/L); 3. Patients are dependent on or not response to glucocorticoids; Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) at least 3 months and the platelet is not increasing in the last 4 weeks; 4. Understand the research program and voluntarily signed informed consent. ;Inclusion criteria: 1. Patients aged between 11 to 65 years male and female; 2. The clinical diagnosis is refractory or chronic ITP patients which need treatment (platelet count < 30 x 10^9/L); 3. Patients are dependent on or not response to glucocorticoids; Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) at least 3 months and the platelet is not increasing in the last 4 weeks; 4. Understand the research program and voluntarily signed informed consent. ;Inclusion criteria: 1. Patients aged between 11 to 65 years male and female; 2. The clinical diagnosis is refractory or chronic ITP patients which need treatment (platelet count < 30 x 10^9/L); 3. Patients are dependent on or not response to glucocorticoids; Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) at least 3 months and the platelet is not increasing in the last 4 weeks; 4. Understand the research program and voluntarily signed informed consent. ;Inclusion criteria: 1. Patients aged between 11 to 65 years male and female; 2. The clinical diagnosis is refractory or chronic ITP patients which need treatment (platelet count < 30 x 10^9/L); 3. Patients are dependent on or not response to glucocorticoids; Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) at least 3 months and the platelet is not increasing in the last 4 weeks; 4. Understand the research program and voluntarily signed informed consent. ;Inclusion criteria: 1. Patients aged between 11 to 65 years male and female; 2. The clinical diagnosis is refractory or chronic ITP patients which need treatment (platelet count < 30 x 10^9/L); 3. Patients are dependent on or not response to glucocorticoids; Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) at least 3 months and the platelet is not increasing in the last 4 weeks; 4. Understand the research program and voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients participated in other clinical trials in one month; 2. Pregnancy or breastfeeding women; 3. Megakaryophthisis; 4. The following biochemical indexes: ALT/AST is greater than 1.5 times the normal limit, total bilirubin, serum creatinine and alkaline phosphatase 1.2 times greater than normal; 5. Patients received with mabthera and splenectomy treatment in six monthes; 6. HIV infection, positive hepatitis C antibody or positive hepatitis B surface antigen; 7. Patients with arrhythmia; 8. Poor control of hypertension or active digestive tract ulcer; 9. Uncontrolled convulsive disease or mental illness; 10. Allergic to aminophylline; 11. Receiving the medicine of rofluorist.;Exclusion criteria: 1. Patients participated in other clinical trials in one month; 2. Pregnancy or breastfeeding women; 3. Megakaryophthisis; 4. The following biochemical indexes: ALT/AST is greater than 1.5 times the normal limit, total bilirubin, serum creatinine and alkaline phosphatase 1.2 times greater than normal; 5. Patients received with mabthera and splenectomy treatment in six monthes; 6. HIV infection, positive hepatitis C antibody or positive hepatitis B surface antigen; 7. Patients with arrhythmia; 8. Poor control of hypertension or active digestive tract ulcer; 9. Uncontrolled convulsive disease or mental illness; 10. Allergic to aminophylline; 11. Receiving the medicine of rofluorist.;Exclusion criteria: 1. Patients participated in other clinical trials in one month; 2. Pregnancy or breastfeeding women; 3. Megakaryophthisis; 4. The following biochemical indexes: ALT/AST is greater than 1.5 times the normal limit, total bilirubin, serum creatinine and alkaline phosphatase 1.2 times greater than normal; 5. Patients received with mabthera and splenectomy treatment in six monthes; 6. HIV infection, positive hepatitis C antibody or positive hepatitis B surface antigen; 7. Patients with arrhythmia; 8. Poor control of hypertension or active digestive tract ulcer; 9. Uncontrolled convulsive disease or mental illness; 10. Allergic to aminophylline; 11. Receiving the medicine of rofluorist.;Exclusion criteria: 1. Patients participated in other clinical trials in one month; 2. Pregnancy or breastfeeding women; 3. Megakaryophthisis; 4. The following biochemical indexes: ALT/AST is greater than 1.5 times the normal limit, total bilirubin, serum creatinine and alkaline phosphatase 1.2 times greater than normal; 5. Patients received with mabthera and splenectomy treatment in six monthes; 6. HIV infection, positive hepatitis C antibody or positive hepatitis B surface antigen; 7. Patients with arrhythmia; 8. Poor control of hypertension or active digestive tract ulcer; 9. Uncontrolled convulsive disease or mental illness; 10. Allergic to aminophylline; 11. Receiving the medicine of rofluorist.;Exclusion criteria: 1. Patients participated in other clinical trials in one month; 2. Pregnancy or breastfeeding women; 3. Megakaryophthisis; 4. The following biochemical indexes: ALT/AST is greater than 1.5 times the normal limit, total bilirubin, serum creatinine and alkaline phosphatase 1.2 times greater than normal; 5. Patients received with mabthera and splenectomy treatment in six monthes; 6. HIV infection, positive hepatitis C antibody or positive hepatitis B surface antigen; 7. Patients with arrhythmia; 8. Poor control of hypertension or active digestive tract ulcer; 9. Uncontrolled convulsive disease or mental illness; 10. Allergic to aminophylline; 11. Receiving the medicine of rofluorist.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the effectiveness; | — |
Secondary
| Measure | Time frame |
|---|---|
| safety; | — |
Countries
China
Contacts
Public ContactKesheng Dai;Kesheng Dai;Kesheng Dai;Kesheng Dai;Kesheng Dai ;;;;
The First Affiliated Hospital of Soochow University;The First Affiliated Hospital of Soochow University;The First Affiliated Hospital of Soochow University;The First Affiliated Hospital of Soochow University;The First Affiliated Hospital of Soochow University
Outcome results
None listed